John Overdeck’s Pulse Biosciences PLSE Stock Holding History

John Overdeck’s Portfolio PLSE Stock Details PLSE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-59,636	Closed	-$290K	–	2846
2022 Q1	$290K	Buy	+59,636	New	+$488K	﹤0.01%	2224
2021 Q4	–	Sell	-21,074	Closed	-$455K	–	4742
2021 Q3	$455K	Sell	21,074 -50,056	-70%	-$1.08M	﹤0.01%	3345
2021 Q2	$1.17M	Buy	71,130 +6,929	+11%	+$132K	﹤0.01%	2347
2021 Q1	$1.52M	Buy	+64,201	New	+$1.92M	﹤0.01%	1929

Other funds holding PLSE

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

State of Wisconsin Investment Board Madison, Wisconsin $49.6B AUM 39.59% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

GAM

Griffin Asset Management New York $949M AUM 24.98% 1-Year Est. Return

Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return

John Overdeck's PLSE Position: Q2 2022 in Review

John Overdeck sold out of Pulse Biosciences (PLSE) in Q2 2022, closing a stake of 59,636 shares — an estimated $290K sold.

John Overdeck first reported a position in PLSE in Q1 2021 and held it in 4 quarters. The position peaked at $1.52M in Q1 2021. 44 funds tracked by Wall St. Rank hold PLSE as of Q2 2022.

John Overdeck reported no remaining Pulse Biosciences position as of Q2 2022 after selling out during the quarter.
John Overdeck sold 59,636 Pulse Biosciences shares in Q2 2022, an estimated $290K.
John Overdeck first reported a position in Pulse Biosciences in Q1 2021 and held it in 4 quarters.
John Overdeck's Pulse Biosciences position peaked at $1.52M in Q1 2021.
44 funds tracked by Wall St. Rank held Pulse Biosciences as of Q2 2022.

Based on Two Sigma Investments's 13F filing for Q2 2022, filed 15 Aug 2022.